DiasensTM and GlucoLiveTM are designed for diabetic, Chronic Kidney Disease (CKD), and post-
transplant patients who require continuous glycaemic surveillance and integrated remote care
The next-gen CGM is paired with AI-powered analytics and a dedicated clinician remote-
monitoring dashboard which is integrated with GoodFlipTM app designed by TatvaCareTM
Zydus Lifesciences Limited (“Zydus”), an innovation-led global life sciences company, today announced its
new offering companion diagnostics portfolio. The company will be launching DiasensTM and GlucoLiveTM,
next-generation Continuous Glucose Monitoring (CGM) devices that combine artificial intelligence-
powered insights, and integrated remote care capabilities. The CGM system is designed to monitor glucose
with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem connecting patients,
caregivers, and clinicians in real time.
Zydus has partnered with Digicare Health Solutions Private Limited (TatvaCareTM), a healthcare technology
company to help the patients gain access to its proprietary, integrated care ecosystem GoodFlipTM to provide
AI-powered report analysis, personalised diet and exercise coaching, doctor consultations, diagnostic lab
booking, and a comprehensive medical record vault – all in a single mobile application.
Speaking on the launch, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Limited, said, “The launch
of DiasensTM and GlucoLiveTM strengthen our companion diagnostics portfolio for chronic disease
management. Focused on patient-centric convenience and better quality of life, these CGMs powered by AI
technology, will give patients real-time access to key glycaemic data on their mobile devices, simplifying
monitoring and control. The convergence of science, innovation, health and technology is critical for patients
managing chronic diseases like diabetes, CKD, or organ transplant – offering a quick, reliable, and safe
glucose monitoring solution with utmost convenience.”
India is home to over 101 million adults living with diabetes – the second-highest burden globally – with an
additional 136 million in the pre-diabetic stage, according to the ICMR-INDIAB study published in The
Lancet Diabetes & Endocrinology. Diabetes is also the leading cause of Chronic Kidney Disease in India,
with 25–40% of CKD patients having a diabetes history. An estimated 2,00,000 patients require kidney
transplants and 25,000 require liver transplants annually, many of whom develop new-onset diabetes due to
immunosuppressive therapies.
Despite this burden, most glucose monitoring in India remains episodic – limited to periodic finger-prick
tests or laboratory HbA1c checks every three to six months. Existing CGM devices in the Indian market
predominantly rely on NFC technology, requiring patients to manually scan the sensor to retrieve readings.
This creates gaps in data continuity, delays clinical intervention, and places the burden of vigilance entirely
on the patient.
DiasensTM and GlucoLiveTM will enable automatic streaming of glucose readings to the patient’s smartphone every three minutes – without manual scanning – ensuring uninterrupted capture, including overnight reading and in emergencies. Through TatvaCareTM’s GoodFlipTM app, AI analytics will detect trends, flags hypo- /hyperglycaemic episodes, link fluctuations to food and activity, and generate actionable insights. A clinician dashboard will support remote monitoring, early intervention, and data-driven treatment adjustments.
